Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

New Weight-Loss Injection CBL-514 Targets Fat Cells and Prevents Weight Regain

4w ago October 2, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

A new weight-loss injection called CBL-514, which selectively induces apoptosis of fat cells, will be presented at the EASD annual meeting in Milan. The drug shows promise in reducing fat levels and preventing weight regain after GLP-1 receptor agonist treatment, according to Dr. W. Timothy Garvey. This development could have implications for healthcare advancements in Iran.

🔍 Quick Context Guide
💡 Bottom Line: The introduction of CBL-514 could revolutionize weight management strategies, particularly in countries like Iran.

👥 Key Players

Dr. W. Timothy Garvey MENTIONED
Lead researcher and presenter
"His research could influence obesity treatment protocols in Iran, where obesity is a growing health concern."
European Association for the Study of Diabetes (EASD) MENTIONED
Organizing body for the annual meeting
"EASD is a significant platform for diabetes research, impacting global health policies and practices."

📰 What Happened

A new weight-loss injection called CBL-514, which targets fat cells, will be presented at the EASD annual meeting. It shows promise in reducing fat and preventing weight regain after other treatments.

  • CBL-514 selectively induces apoptosis of fat cells.
  • It may help patients maintain weight loss after stopping GLP-1 receptor agonist drugs.

💡 Why It Matters

🇮🇷 For Iran: Iran faces a rising obesity epidemic, and new treatments could improve public health outcomes.
🌍 Regional: Other countries in the region may also benefit from advancements in obesity treatment, impacting healthcare systems.
🌐 International: This development could influence global pharmaceutical markets and obesity treatment strategies.

📚 Background

Obesity is a significant health issue worldwide, linked to various chronic diseases. New treatments like CBL-514 represent a potential shift in how obesity is managed.

Obesity treatment Diabetes management
📡 Source: NEUTRAL
📊 Confidence: 70%
The information is presented in a scientific context, focusing on research findings and their implications.

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2). Studies show that the new drug, CBL-514, reduces levels of subcutaneous and visceral fat. The data also suggest that it helps limit weight regain after people stop taking GLP-1 receptor agonist drugs (GLP1-RAs), says Dr. W. Timothy Garvey of the University of Alabama at Birmingham.

🏷️ Entities Mentioned

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →